keyword
MENU ▼
Read by QxMD icon Read
search

Bladder cancer, biomarkers

keyword
https://www.readbyqxmd.com/read/28325826/a-phase-ii-randomized-double-blind-presurgical-trial-of-polyphenon-e-in-bladder-cancer-patients-to-evaluate-pharmacodynamics-and-bladder-tissue-biomarkers
#1
Jason R Gee, Daniel R Saltzstein, KyungMann Kim, Jill M Kolesar, Wei Huang, Thomas C Havighurst, Barbara W Wollmer, Jeanne Stublaski, Tracy Downs, Hasan Mukhtar, Margaret House, Howard L Parnes, Howard H Bailey
We performed a phase 2 pharmacodynamic, prevention trial of Polyphenon E® (a green tea polyphenol formulation primarily consisting of epigallocatechin gallate (EGCG)) in patients prior to bladder cancer surgery. Patients with a bladder tumor were randomized to receive Polyphenon E® containing either 800 or 1200 mg of EGCG or placebo for 14 to 28 days prior to TURBT or cystectomy. The primary objective was to compare the post-intervention EGCG tissue levels in patients receiving Polyphenon E® as compared to placebo...
March 21, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28306559/immunotherapy-a-new-treatment-paradigm-in-bladder-cancer
#2
Nicole N Davarpanah, Akira Yuno, Jane B Trepel, Andrea B Apolo
PURPOSE OF REVIEW: T-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor, became the first new drug approved in metastatic urothelial carcinoma (mUC) in over 30 years. In 2017, nivolumab was also approved for the same indication. This overview of checkpoint inhibitors in clinical trials focuses on novel immunotherapy combinations, predictive biomarkers including mutational load and neoantigen identification, and an evaluation of the future of bladder cancer immunotherapy...
March 16, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28295307/high-expression-of-insulin-receptor-on-tumor-associated-blood-vessels-in-invasive-bladder-cancer-predicts-poor-overall-and-progression-free-survival
#3
Filip Roudnicky, Lothar C Dieterich, Cedric Poyet, Lorenz Buser, Peter Wild, Dave Tang, Peter Camenzind, Chien Hsien Ho, Vivianne I Otto, Michael Detmar
Bladder cancer is a frequently recurring disease with a very poor prognosis when progressed to invasive stages, and tumor-associated blood vessels play a crucial role in this process. In order to identify novel biomarkers associated with progression, we isolated blood vascular endothelial cells (BECs) from human invasive bladder cancers and matched normal bladder tissue, and found that tumor-associated BECs greatly upregulated the expression of insulin receptor (INSR). High expression of INSR on BECs of invasive bladder cancers was significantly associated with shorter progression-free and overall survival...
March 14, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28293425/podocalyxin-like-and-rna-binding-motif-protein-3-are-prognostic-biomarkers-in-urothelial-bladder-cancer-a-validatory-study
#4
Karolina Boman, Gustav Andersson, Christoffer Wennersten, Björn Nodin, Göran Ahlgren, Karin Jirström
BACKGROUND: Urothelial bladder cancer (UBC) is a disease that often is discovered when the tumour is non-muscle invasive, i.e. in Ta or T1 stage. Some patients will progress into muscle-invasive disease, a potentially deadly condition. Although there are some prognostic models, the need for prognostic and predictive biomarkers is considerate and urgent. Membranous expression of podocalyxin-like protein 1 (PODXL) and low expression of the RNA-binding motif 3 (RBM3) has previously been shown to be associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer, including UBC...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28291637/is-the-cancer-genome-atlas-tcga-bladder-cancer-cohort-representative-of-invasive-bladder-cancer
#5
Roland Seiler, Peter C Black, George Thalmann, Arnulf Stenzl, Tilman Todenhöfer
PURPOSE: The Cancer Genome Atlas (TCGA) Research Consortium has conducted a comprehensive molecular characterization of invasive bladder cancer (BCa). This open-access dataset has become the critical reference for studying biomarkers and mechanisms of disease in BCa. In order for this data to be considered representative, and to allow comparisons of markers between cohorts, clinicopathologic characteristics of this cohort need to conform to those established for this disease state. The aim of this study was to critically evaluate clinicopathologic characteristics and outcomes of the TCGA BCa cohort in comparison with published cystectomy series...
March 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28288658/prostate-cancer-treated-with-brachytherapy-an-exploratory-study-of-dose-dependent-biomarkers-and-quality-of-life
#6
Sarah O S Osman, Simon Horn, Darren Brady, Stephen J McMahon, Ahamed B Mohamed Yoosuf, Darren Mitchell, Karen Crowther, Ciara A Lyons, Alan R Hounsell, Kevin M Prise, Conor K McGarry, Suneil Jain, Joe M O'Sullivan
BACKGROUND: Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. METHODS: Twelve patients treated with (125)I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study...
March 14, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28287737/large-scale-srm-screen-of-urothelial-bladder-cancer-candidate-biomarkers-in-urine
#7
Elodie Duriez, Christophe D Masselon, Cédric Mesmin, Magali Court, Kevin Demeure, Yves Allory, Nuria Malats, Mariette Matondo, François Radvanyi, Jérôme Garin, Bruno Domon
Urothelial bladder cancer is a condition associated with high recurrence and substantial morbidity and mortality. Non-invasive urinary tests that would detect bladder cancer and tumor recurrence are required to significantly improve patient care. Over the last decade, numerous bladder cancer candidate biomarkers have been identified in the context of extensive proteomics or transcriptomics studies. To translate these findings in clinically useful biomarkers, the systematic evaluation of these candidates remains the bottleneck...
March 13, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/28282341/new-developments-in-the-management-of-nonmuscle-invasive-bladder-cancer
#8
Mark D Tyson, Daniel Lee, Peter Clark
PURPOSE OF REVIEW: In this review, we summarize the core principles in the management of nonmuscle invasive bladder cancer (NMIBC) with an emphasis on new developments that have emerged over the last year. RECENT FINDINGS: NMIBC has a propensity to recur and progress. Risk stratification has facilitated appropriate patient selection for treatment but improved tools, including biomarkers, are still needed. Enhanced cystoscopy with photodynamic imaging and narrow band imaging show promise for diagnosis, risk stratification, and disease monitoring and has been formally recommended this year by the American Urological Association...
March 9, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28261684/evaluation-of-zinc-finger-e-box-binding-homeobox-1-and-transforming-growth-factor-beta2-expression-in-bladder-cancer-tissue-in-comparison-with-healthy-adjacent-tissue
#9
Ali Mahdavinezhad, Reza Yadegarazari, Seyed Habibollah Mousavi-Bahar, Jalal Poorolajal, Mohammad Jafari, Mohammad Ali Amirzargar, Hosein Effatpanah, Massoud Saidijam
PURPOSE: The fifth most common cancer is allocated to bladder cancer (BC) worldwide. Understanding the molecular mechanisms of BC invasion and metastasis to identify target therapeutic strategies will improve disease survival. So the aim of this study was to measure expression rate of zinc finger E-box binding homeobox 1 (ZEB1) and transforming growth factor-beta2 (TGF-β2) mRNA in tissue samples of patients with BC and its healthy adjacent tissue samples and their association with muscle invasion, size and grade of the tumor...
March 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28260919/overexpression-of-the-long-non-coding-rna-linc-ubc1-is-associated-with-poor-prognosis-and-facilitates-cell-proliferation-migration-and-invasion-in-colorectal-cancer
#10
Xunfeng Gao, Jianfan Wen, Peng Gao, Guowei Zhang, Gangqing Zhang
Long non-coding RNAs (lncRNAs) serve comprehensive roles in various diseases, including cancer. lncRNA upregulated in bladder cancer 1 (linc-UBC1) is a notable biomarker of prognosis in certain cancer types; however, its involvement in the progression of colorectal cancer (CRC) remains unknown. The present study aimed to investigate the expression of linc-UBC1 in patients with CRC and to investigate its effect on CRC cells. The expression levels of linc-UBC1 were estimated by reverse transcription-quantitative polymerase chain reaction in clinical CRC specimens and matched adjacent non-tumor mucosa from 96 cases of CRC, as well as in a number of CRC cell lines...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28245143/dwi-as-an-imaging-biomarker-for-bladder-cancer
#11
Soichiro Yoshida, Taro Takahara, Thomas C Kwee, Yuma Waseda, Shuichiro Kobayashi, Yasuhisa Fujii
OBJECTIVE: DWI has been increasingly applied in the management of bladder cancer. In this article, we discuss the role of DWI as an imaging biomarker for bladder cancer. CONCLUSION: The DWI signal is derived from the motion of water molecules, which represents the physiologic characteristics of the tissue of interest. The emerging evidence highlights the utility of DWI for bladder cancer detection and characterization. DWI is a potentially useful tool to individualize treatment strategies...
February 28, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28214283/prognostic-role-of-n-cadherin-expression-in-patients-with-non-muscle-invasive-bladder-cancer
#12
Mohammad Abufaraj, Shahrokh F Shariat, Andrea Haitel, Marco Moschini, Beat Foerster, Piotr Chłosta, Kilian Gust, Marek Babjuk, Alberto Briganti, Pierre I Karakiewicz, Walter Albrecht
PURPOSE: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy. PATIENTS AND METHODS: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28212556/urinary-cell-microrna-based-prognostic-classifier-for-non-muscle-invasive-bladder-cancer
#13
Mercedes Ingelmo-Torres, Juan José Lozano, Laura Izquierdo, Albert Carrion, Meritxell Costa, Lidia Gómez, María José Ribal, Antonio Alcaraz, Lourdes Mengual
Current prognostic tools for non-muscle invasive bladder cancer (NMIBC) do not have enough discriminative capacity to predict the risk of tumour progression. This study aimed to identify urinary cell microRNAs that may be useful as non-invasive predictive biomarkers of tumour progression in NMIBC patients. To this end, 210 urine samples from NMIBC patients were included in the study. RNA was extracted from urinary cells and expression of 8 microRNAs, previously described by our group, was analysed by quantitative PCR...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28209906/first-evaluation-of-pet-based-human-biodistribution-and-dosimetry-of-18-f-faza-a-tracer-for-imaging-tumor-hypoxia
#14
Annarita Savi, Elena Incerti, Federico Fallanca, Valentino Bettinardi, Francesca Rossetti, Cristina Monterisi, Antonia Compierchio, Giampiero Negri, Piero Zannini, Luigi Gianolli, Maria Picchio
Fluorine-18 labelled fluoroazomycinarabinoside ((18)F-FAZA) is a positron emission tomography (PET) biomarker for non-invasive identification of regional tumor hypoxia. Aim of the present Phase I study was to firstly evaluate in non-small cell lung cancer patients the human biodistribution and dosimetry of (18)F-FAZA. Methods: Five patients awaiting surgical resection after histologically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled for the study. The patients underwent a PET/computed tomography (CT) study after the injection of 371±32 MBq of (18)F-FAZA...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28207521/quantitative-assessment-of-the-relationship-between-rassf1a-gene-promoter-methylation-and-bladder-cancer-prisma
#15
Leyun Zhan, Bingyi Zhang, Yaojun Tan, Chengliang Yang, Chenhong Huang, Qiongya Wu, Yulin Zhang, Xiaobo Chen, Mi Zhou, Aihua Shu
BACKGROUND: Methylation of the Ras-association domain family 1 isoform A (RASSF1A) gene promoter region is thought to participate in the initiation and development of many different cancers. However, in bladder cancer the role of RASSF1A methylation was unclear. To evaluate the relationship between RASSF1A methylation and bladder cancer, a quantitative assessment of an independent meta-analysis was performed. In addition, a DNA methylation microarray database from the cancer genome atlas (TCGA) project was used to validate the results of the meta-analysis...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28199978/down-regulation-of-lncrna-casc2-promotes-cell-proliferation-and-metastasis-of-bladder-cancer-by-activation-of-the-wnt-%C3%AE-catenin-signaling-pathway
#16
Zhijun Pei, Xian Du, Yafeng Song, Lin Fan, Fuyan Li, Yan Gao, Ruimin Wu, Yijia Chen, Wei Li, Hong Zhou, Yi Yang, Jing Zeng
Long noncoding RNAs cancer susceptibility candidate 2 (CASC2) have been demonstrated as playing crucial regulatory roles in a few of cancers. However, the biological function of lncRNA CASC2 in bladder cancer are still unclear. In this study, we found that lncRNA CASC2 was significantly down-regulated in bladder cancer tissues and cell lines by quantitative real time-PCR and associated with advanced TNM stage (III/IV). Moreover, overexpression of lncRNA CASC2 remarkably reduced the cell growth, migration and invasion, as well as promoted early apoptosis of bladder cancer cell in vitro...
February 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28193625/deep-sequencing-of-urinary-rnas-for-bladder-cancer-molecular-diagnostics
#17
Mandy L Y Sin, Kathleen E Mach, Rahul Sinha, Fan Wu, Dharati Trivedi, Emanuela Altobelli, Kristin C Jensen, Debashis Sahoo, Ying Lu, Joseph C Liao
PURPOSE: The majority of bladder cancer patients present with localized disease and are managed by transurethral resection. However, the high rate of recurrence necessitates lifetime cystoscopic surveillance. Developing a sensitive and specific urine-based test would significantly improve bladder cancer screening, detection, and surveillance. EXPERIMENTAL DESIGN: RNA-seq was used for biomarker discovery to directly assess the gene expression profile of exfoliated urothelial cells in urine derived from bladder cancer patients (n=13) and controls (n=10)...
February 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28167242/epigenome-wide-dna-methylation-profiling-identifies-differential-methylation-biomarkers-in-high-grade-bladder-cancer
#18
Ekaterina Olkhov-Mitsel, Andrea J Savio, Ken J Kron, Vaijayanti V Pethe, Thomas Hermanns, Neil E Fleshner, Bas W van Rhijn, Theodorus H van der Kwast, Alexandre R Zlotta, Bharati Bapat
Epigenetic changes, including CpG island hypermethylation, occur frequently in bladder cancer (BC) and may be exploited for BC detection and distinction between high-grade (HG) and low-grade (LG) disease. Genome-wide methylation analysis was performed using Agilent Human CpG Island Microarrays to determine epigenetic differences between LG and HG cases. Pathway enrichment analysis and functional annotation determined that the most frequently methylated pathways in HG BC were enriched for anterior/posterior pattern specification, embryonic skeletal system development, neuron fate commitment, DNA binding, and transcription factor activity...
April 2017: Translational Oncology
https://www.readbyqxmd.com/read/28165132/nonmuscle-invasive-bladder-cancer-what-s-changing-and-what-has-changed
#19
Ramanitharan Manikandan, Oscar Rodriguez, Rubén Parada, Joan Palou Redorta
PURPOSE: Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette-Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish 'what changes has already occurred and what is expected in the future' in NMIBC...
February 3, 2017: Urologia
https://www.readbyqxmd.com/read/28164165/accuracy-of-self-reported-smoking-exposure-among-bladder-cancer-patients-undergoing-surveillance-at-a-tertiary-referral-center
#20
Alan E Thong, Stacey Petruzella, Irene Orlow, Emily C Zabor, Behfar Ehdaie, Jamie S Ostroff, Bernard H Bochner, Helena Furberg Barnes
BACKGROUND: Smoking is a risk factor for developing bladder cancer (BCa). Even though continued exposure after diagnosis may adversely affect prognosis, patients may be reluctant to disclose to their physicians that they are currently smoking, leading to inaccurate reporting of exposure and missed opportunities to deliver smoking-cessation advice and treatment in the context of cancer care. OBJECTIVE: We examined the extent of misclassification of recent smoking exposure among patients undergoing BCa surveillance...
October 2016: European Urology Focus
keyword
keyword
70954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"